Safety of Titrated Immediate-release Tolvaptan in Subjects with Autosomal Dominant Polycystic Kidney Disease

Status: open

A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease

Treatment for Polycystic Kidney Disease

Contact Us Or call 251-660-5243

Description

The purpose of the study is to evaluate and describe the long term safety of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD

Sponsors

This trial is sponsored by Otsuka Pharmaceutical.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.